American Gun Owners (AGO) to Present at Centurion One Capital 6th Annual LA Summit
Austin, Texas--(Newsfile Corp. - May 28, 2025) - American Gun Owners (AGO), the go-to platform for first-time gun buyers saving customers the most time and money, is pleased to announce it will be presenting at the Centurion One Capital 6th Annual LA Summit, held at the iconic Beverly Hills Hotel from Monday, June 2nd to Thursday, June 5th , 2025, in Los Angeles, California.
Michael Pierce, CEO & Founder, will also be attending investor meetings and participating on a panel discussion. "My team is excited to share upcoming AGO updates, which will revolutionize the first-time gun buyer journey."
Centurion One Capital 6th Annual LA Summit
Format: Presentations, Panel Discussions and 1 X 1 Investor MeetingsPresentation Dates: Wednesday, June 4th and Thursday, June 5th, 2025Time: 9:00 AM PDT - 5:00 PM PDT Venue: The Beverly Hills Hotel
For more information and registration details, please visit: https://www.centuriononecapital.com/la-summit.
About Centurion One Capital
Centurion One Capital ("Centurion One") is the premier independent Investment Banking firm dedicated to fueling the growth and success of growth companies in North America. With an unwavering commitment to delivering comprehensive financial solutions and strategic guidance, Centurion One is a trusted strategic partner and catalyst to propel issuers to unlock their full potential.
Our team comprises seasoned professionals who combine extensive financial expertise with deep knowledge of various sectors. We take a proactive and results-driven approach, working closely with our clients to develop tailored strategies and execute transactions that maximize value and drive long-term success.
Centurion One - Empowering Growth. Driving Innovation. Partnering for Success.
For more information about Centurion One, visit www.centuriononecapital.com.
American Gun Owners (AGO)
Per: Michael Pierce CEO & Founder
About AGO
The all-in-one platform for first-time firearm owners. Our experts pick the right firearm, a discounted annual subscription for ammo and range access, self-defense insurance, and other accessories, guaranteeing the best prices and an easy experience for new owners.
Learn more: www.americangunowners.com
Contacts
MediaAmerican Gun Owners (AGO)info@americangunowners.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253600
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending patent protection through to December 2043. The Orange Book is published by the U.S. Food and Drug Administration (FDA) and lists all approved prescription drug products, along with patent and exclusivity information. Inclusion signifies FDA recognition of the revised formulation's approved status and its intellectual property protection. WOBURN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the inclusion of the patent for its propylene glycol-free formulation of Ameluz® nanoemulsion gel in the US Food and Drug Administration's (FDA's) publication 'Approved Drug Products with Therapeutic Equivalence Evaluations' (commonly known as the Orange Book). The Orange Book is a key reference for healthcare providers, pharmacists, and payers and is the definitive source for identifying FDA-approved drug products. Inclusion of a drug in the Orange Book confirms that the FDA recognizes that the drug meets their rigorous standards for safety, efficacy, and quality. In addition, patents listed confer intellectual property protections which may include the drug's composition, formulation, or specific uses. Listing of the patent for the propylene glycol-free formulation of Ameluz® prevents generic competition as long as the patent is valid, which currently is December 2043. The revised formulation, which eliminates propylene glycol—a well-known allergen for some patients1—demonstrates Biofrontera's continued commitment to innovation and patient-centric development. It offers a significant improvement for individuals who are sensitive to this excipient without compromising the treatment's effectiveness. The patent for the revised formulation of Ameluz® was issued on April 22, 2025, and lasts until December 8, 2043. The formulation itself was accepted by the FDA and has been in use since 2024. 'We are proud to announce the inclusion of the patent for our propylene glycol-free formula in the Orange Book,' said Dr Hermann Luebbert, CEO and Chairman of Biofrontera Inc. 'This recognition validates the differentiated profile of our propylene glycol-free formulation, offering physicians and patients a formulation that reduces the potential for allergic reactions while maintaining the efficacy of Ameluz® RhodoLED PDT.' References: Jacob SE, et al. 'Contact Allergy to Propylene Glycol: A Review.' Dermatitis. 2008;19(3):157–163. About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit and follow Biofrontera on LinkedIn and Twitter. Forward-Looking Statements Certain statements in this press release may constitute 'forward-looking statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to Biofrontera's commercial opportunities and the commercial success of its licensed products. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of any extraordinary external events; any changes in the Company's relationship with its licensors; the ability of the Company's licensors to fulfill their obligations to the Company in a timely manner; the Company's ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company's ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company's licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED and/or RhodoLED XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz in combination with BF- RhodoLED and/or RhodoLED XL is consistent with the Company's expectations; the Company's ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing; and other factors that may be disclosed in the Company's filings with the Securities and Exchange Commission (the 'SEC'), which can be obtained on the SEC's website at Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. Contact:Investor RelationsAndrew Barwicki1-516-662-9461ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Intercept
5 days ago
- The Intercept
The Intercept Sues for Records About Arizona's Financial Surveillance Dragnet
The Intercept filed a public records lawsuit on Monday for documents about a financial surveillance program run by the Arizona attorney general's office for more than a decade. For the past year, the attorney general's office has denied multiple requests for records about its relationship with the Transaction Record Analysis Center, or TRAC, a nonprofit organization that runs a massive database containing details about millions of wire transfers sent through Western Union and other companies. The database, which is fueled by administrative subpoenas issued by the Arizona attorney general's office, offers an intimate glimpse into the financial lives of millions of immigrants and U.S. citizens alike. Over the years, Immigration and Customs Enforcement has played an outsized role in TRAC, not just as a top user of the wire transfer data but also as another data pipeline, via subpoenas that alarmed civil liberties watchdogs. 'The public has the right to know about mass government surveillance of its citizens,' said Heather E. Murray, associate director of Cornell Law School's First Amendment Clinic, which is representing The Intercept in the lawsuit, in an emailed statement. 'Because TRAC is indisputably performing a core governmental function, the records that The Intercept seeks must be released by the AGO and TRAC to fulfill their transparency obligations under the Arizona Public Records Law.' Ben Rundall, a partner at Zwillinger Wulkan in Phoenix, is also representing The Intercept in the case, which was filed in Maricopa County Superior Court. 'This completely defies the spirit and purpose of the [Arizona public records law].' In response to The Intercept's records request last year, TRAC claimed it is not subject to public records disclosure requirements because of its nonprofit structure. But TRAC was established by the attorney general's office in 2014, and records show close coordination over the years between agency officials and TRAC staff — who sometimes used official government email addresses. For years, one TRAC staff member even helped draft the administrative subpoenas, which she sent to the attorney general's office for official signature before they were served on Western Union and the other money transfer businesses. The attorney general's office previously released hundreds of documents about TRAC's structure and operations to the American Civil Liberties Union. But under Attorney General Kris Mayes, the office now claims it has no obligation to release similar materials because they are in TRAC's possession. 'Stated directly, the AGO and TRAC are engaging in gamesmanship to avoid providing records about their public functions,' reads The Intercept's court filing. 'When a request is made to the AGO, it claims TRAC has the record. When a request is made to TRAC, it claims the AGO has the record. This completely defies the spirit and purpose of the [Arizona public records law].' The attorney general's office also previously disclosed to the ACLU more than 100 copies of subpoenas the agency has sent under the state's racketeering law to more than two dozen companies since 2014. But in response to The Intercept's request, the agency said releasing any more subpoenas would violate the racketeering law itself. 'We are correcting the previous administration's error and following the law,' wrote Richie Taylor, communications director for Mayes's office, in an email last year. An ACLU attorney, Nate Freed Wessler, previously called the agency's argument about disclosing the subpoenas 'wrong and borderline frivolous.' The racketeering law 'has nothing to do with the AGO's responsibility to disclose records,' The Intercept argues in its filing. 'Withholding these records does not comport with any exception to public access provided in Arizona law.'
Yahoo
5 days ago
- Yahoo
Meet With iQor CXBPO™ at Customer Contact Week Las Vegas 2025
Industry Experts to Showcase infinityAiQ™ Platform and Next-Gen VOC Analytics FT. LAUDERDALE, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- Leaders from iQor CXBPO™, an award-winning customer experience business process outsourcing (BPO) solutions provider unifying AI, analytics, and human expertise, will exhibit at Customer Contact Week (CCW) Las Vegas 2025 at Caesars Forum from June 10 to 12. As the world's largest customer contact event, CCW provides a premier platform for CX leaders to explore cutting-edge innovations and strategic insights shaping the future of customer service. Attendees are invited to connect with iQor's CX experts to learn how global brands are leveraging the company's operational excellence, AI-enabled solutions, and next-generation VOC analytics to drive efficiency, reduce costs, and elevate customer satisfaction. iQor will highlight the power of its infinityAiQ™ platform, the engine that powers its revolutionary CXBPO™ model, turning every customer interaction into business intelligence and every CX process into a growth opportunity — unifying people, processes, and insights to deliver value like never before. Backed by a global team of 180+ data scientists, analysts, and Ph.D.s., iQor's integration of AI and analytics combines proprietary tools, enriched datasets, and advanced partner technologies for exceptional CX. iQor will also demonstrate the benefits of its collaboration with OpenAI. iQor is the first CXBPO to integrate OpenAI's advanced language models into its proprietary analytics platform, empowering brands to instantly analyze customer sentiment and behavior across millions of interactions. This real-time intelligence enables personalized experiences, proactive issue resolution, and smarter decision-making throughout the customer journey. Stop by Booth 1624 in the Expo Hall between 8 a.m. and 5 p.m. PDT on Tuesday, June 10; between 8 a.m. and 6 p.m. PDT on Wednesday, June 11; and between 8 a.m. and 5:30 p.m. PDT on Thursday, June 12, to explore how AI-driven solutions can transform your customer experience strategy. To book time with an iQor CX leader, visit the iQor CCW Las Vegas 2025 event page. To learn more about CCW Las Vegas 2025, visit the official event website. About iQor CXBPO™iQor CXBPO™ is a trusted partner in intelligent customer experience solutions, delivering exceptional results for global brands. With 40,000 employees across 10 countries, we combine 30 years of industry expertise with cutting-edge AI-driven innovations to optimize customer interactions at every stage. Our agile, scalable solutions ensure seamless omnichannel engagement, driving loyalty and measurable business success. Recognized as a Great Place to Work® and a leader in CX excellence, we elevate performance through a people-first approach, operational expertise, and secure, technology-enabled solutions. Learn more at CONTACT: Contact Nicole Gobbo Director of Communications
